Ondansetron reduces nausea induced by gastroduodenal stimulation without changing gastric motility

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 271, Issue 4 34-4, 1996, Pages

  Feinle, Christine ^a   Read, Nicholas W ^a,b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b NORTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

5 hydroxytryptamine3 receptors; duodenal lipid; fullness; gastric distension

Indexed keywords

ONDANSETRON; SEROTONIN 3 RECEPTOR;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA; NEUROTRANSMISSION; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROTONINERGIC NERVE; STOMACH DISTENSION; STOMACH INNERVATION; STOMACH MOTILITY; STOMACH MUSCLE; STOMACH PRESSURE;

EID: 0029958673     PISSN: 01931857     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpgi.1996.271.4.g591     Document Type: Article

References (33)

1. 3 receptor antagonist) on gastric emptying of a solid meal in normal subjects. Gut 29: 1249-1252, 1988.
2. Andrews, P. L. R., C. J. Davis, S. Bingham, H. I. M. Davidson, J. Hawthorn, and L. Maskell. The abdominal visceral innervation and the emetic reflex: pathways, pharmacology and plasticity. Can. J. Physiol. Pharmacol. 68: 325-345, 1990.
3. Barbera, R., C. Feinle, and N. W. Read. Abnormal sensitivity to duodenal lipid infusion in patients with functional dyspepsia. Eur. J. Gastroenterol Hepatol. 7: 1051-1058, 1995.
4. Blackshaw, L. A., and D. Grundy. Effects of 5-hydroxytryptamine on discharge of vagal mucosal afferent fibres from the upper gastrointestinal tract of the ferret. J. Auton. Nerv. Syst. 45: 41-50, 1993.
5. Blackwell, C. P., and S. M. Harding. The clinical pharmacology of ondansetron. Eur. J. Cancer Clin. Oncol. 25, Suppl. 1: S21-S24, 1989.
6. Bülbring, E., and A. Crema. The release of 5-hydroxytryptamine in relation to pressure exerted on the intestinal mucosa. J. Physiol. Lond. 146: 18-28, 1959.
7. 3 receptor antagonist, on gastric emptying in the guinea-pig. Br. J. Pharmacol. 91: 263-264, 1987.
8. Davison, J. S., L. Oland, and F. Boissonade. The effects of centrally injected NK1 receptor antagonists on emesis in the ferret (Abstract). Gastroenterology 108, Suppl.: A589, 1995.
9. Farthing, M. J. G. 5-Hydroxytryptamine, and 5-Hydroxytryptamine-3 receptor antagonists. Scand. J. Gastroenterol. 26, Suppl. 188: 92-100, 1991.
10. Feinle, C., R. Barbera, N. W. Read, and D. Grundy. Different amounts of intraduodenal lipid alter gastric sensory but not the motor responses to distension (Abstract). Neurogastroenterol. Motil. 6: 137, 1994.
11. Feinle, C., M. D'Amato, and N. W. Read. CCK-A receptors modulate gastric sensory and motor responses to gastric distension and duodenal lipid. Gastroenterology 110: 1379-1385, 1996.
12. Feinle, C., D. Grundy, and N. W. Read. Effects of isocaloric duodenal carbohydrate and lipid on gastric motor and sensory responses to gastric distension (Abstract). Gastroenterology 106: A1025, 1995.
13. Ferrara, A., M. J. Zinner, and B. M. Jaffe. Intraluminal release of serotonin, substance P and gastrin in the canine small intestine. Dig. Dis. Sci. 32: 289-294, 1987.
14. Gore, S., I. T. Gilmore, C. G. Haigh, S. M. Brownless, H. Stockdale, and A. I. Morris. Colonic transit in man is slowed by ondansetron (GR38032F), a selective 5-hydroxytryptamine receptor (type 3) antagonist. Aliment Pharmacol. Ther. 4: 139-144, 1990.
15. Grundy, D., and T. Scratcherd. Sensory afferents from the gastrointestinal tract. In: Handbook of Physiology. The Gastrointestinal System. Motility and Circulation. Bethesda, MD: Am. Physiol. Soc., 1989, sect. 6, vol. 1, pt. 1., chapt. 16, p. 593-620.
16. 3 receptor antagonists injected into the area postrema inhibit cisplatin induced emesis in the ferret. Br. J. Pharmacol. 97: 247-255, 1989.
17. Hopman, W. P. M., J. B. M. J. Jansen, and C. B. H. W. Lamers. Comparative study of the effects of fat, protein and starch on plasma cholecystokinin in man. Scand. J. Gastroenterol. 20: 843-847, 1985.
18. Houghton, L. A., Y. F. Mangnall, A. Dwivedi, and N. W. Read. Sensitivity to nutrients in patients with non ulcer dyspepsia. Eur. J. Gastroenterol. Hepatol. 5: 109-113, 1993.
19. Jones, A. L., and D. Cunningham. Management of vomiting associated with cytotoxic therapy. Br. J. Hosp. Med. 45: 85-88, 1991.
20. Kalia, M., and M. M. Mesulam. Brain stem projections of sensory and motor components of the vagus complex in the cat. II. Laryngeal, tracheobronchial, pulmonary, cardiac, and gastrointestinal branches. J. Comp. Neurol. 193: 467-508, 1980.
21. Kanarek, R. B., and H. Dushkin. Peripheral serotonin administration selectively reduces fat intake in rats. Pharmacol. Biochem. Behav. 31: 113-122, 1988.
22. Leslie, R. A., D. G. Gwyn, and D. A. Hopkins. The central distribution of the cervical vagus nerve and gastric afferent and efferent projections in the rat. Brain Res. Bull. 8: 37-43, 1982.
23. Lewis, T. Pain. New York; Macmillan, 1942.
24. 2 antagonist ritanserin on food intake and on 5-HT-induced anorexia in the rat. Pharmacol. Biochem. Behav. 26: 333-340, 1987.
25. 3 antagonist ondansetron on gastric emptying in patients with gastric stasis syndrome. Digestion 46: 89-96, 1990.
26. Perez, E. A., P. J. Hesketh, and D. R. Gandara. Serotonin antagonists in the management of cisplatin-induced emesis. Semin. Oncol. 18, Suppl. 3: 73-80, 1991.
27. 3 receptor antagonist, in patients with irritable bowel syndrome. Aliment. Pharmacol. Ther. 7: 175-180, 1993.
28. 3 receptor antagonist ICS 205-930 on fat-delayed gastric emptying and antral motor activity. Br. J. Clin. Pharmacol. 30: 41-48, 1990.
29. Stark, M., Jr., K. Maher, P. Gupta, S. Epstein, R. Cannon, J. Lewis, and S. Benjamin. Visceral afferent blockade with ondansetron (Zofran) increases nociceptive thresholds in patients with chest pain of undetermined etiology (CPUE) (Abstract). Am. J. Gastroenterol. 86: 1305, 1991.
30. 3 receptor antagonist, reduces palatable food consumption in the non-deprived rat. Neuropharmacology 33: 805-811, 1994.
31. 3 receptor antagonist, is a potent and long-lasting antiemetic agent in the ferret and dog. J. Pharmacol. Exp. Ther. 260: 1159-1165, 1992.
32. Zerbib, F., S. Bruley des Varannes, R. C. Oriola, J. McDonaid, J. P. Isal, and J. P. Galmiche. Alosetron does not affect the visceral perception of gastric distension in healthy subjects. Aliment. Pharmacol. Ther. 8: 403-407, 1994.
33. Ziegelboim, J., N. J. Talley, S. F. Phillips, W. S. Harmsen, and A. R. Zinsmeister. Visceral perception in irritable bowel syndrome. Rectal and gastric responses to distension and serotonin type 3 antagonism. Dig. Dis. Sci. 40: 819-827, 1995.